Treatment of refractory, fulminant and macrolide-resistant mycoplasma pneumoniae pneumonia
10.3760/cma.j.issn.1673-4912.2021.01.001
- VernacularTitle:难治性、暴发性及大环内酯类耐药肺炎支原体肺炎的治疗
- Author:
Hengmiao GAO
;
Suyun QIAN
- From:
Chinese Pediatric Emergency Medicine
2021;28(1):1-6
- CountryChina
- Language:Chinese
-
Abstract:
Mycoplasma pneumoniae (MP) is the most common pathogens of community-acquired pneumonia in children.Macrolides are the first-line antibiotics for mycoplasma pneumoniae pneumonia (MPP) treatment.However, in recent years, with macrolide resistant MP (MRMP) becoming prevalent, refractory MPP (RMPP) and fulminant MPP (FMPP) increased significantly.It has become a hot issue for clinicians.This paper reviewed the recent studies on MRMP, RMPP and FMPP, discussed the diagnosis and treatment options for MRMP, RMPP and FMPP in detail.Prioritizing the selection of sensitive antibiotics and early initiation of effective antibiotic therapy, appropriate use of immunoregulatory and anti-inflammatory therapies, and aggressive treatment of complications and co-infections are the keys to RMPP and FMPP therapy.
